Trials / Unknown
UnknownNCT04459754
Fuzheng Yiliu-1010
Based on the Real World Prospective Cohort Study, Two-way Analysis of the Dominant Population and Corresponding Phenotypic Characteristics of Patients With Colorectal Cancer Treated by Fuzheng Yiliu Therapy Combined With Adjuvant Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 189 (estimated)
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction model of dominant population of Fuzheng anti-tumor therapy was constructed by using real-world data and gene expression profile data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fuzheng Yiliu Formulation | The "prescription for colorectal cancer" Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption. |
Timeline
- Start date
- 2020-06-29
- Primary completion
- 2021-12-31
- Completion
- 2024-12-31
- First posted
- 2020-07-07
- Last updated
- 2020-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04459754. Inclusion in this directory is not an endorsement.